Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 123 entries
Sorted by: Best Match Show Resources per page
Integrating Patient Reported Outcomes within Routine Hepatology Care: A Prompt to Action

pipeline programs

Verma M, Younossi Z.
GSID: ZxiiZuzu6PEJ
M Verma, Z Younossi - Hepatology (Baltimore, Md.), 2020 - europepmc.org

Chronic liver disease (CLD) and its complications account for significant morbidity and mortality worldwide. Traditionally, clinical measures such as histologic stage of fibrosis and …

Treatment strategies for chronic hepatitis C prior to and following liver transplantation.

World journal of hepatology

Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A.
PMID: 26783422
World J Hepatol. 2016 Jan 08;8(1):69-73. doi: 10.4254/wjh.v8.i1.69.

Hepatitis C virus (HCV)-related liver disease is the leading indication for liver transplantation (LT) worldwide. However, HCV is an independent predictor of lower survival following LT, and recurrence of HCV post-LT is virtually universal. The historic standard of care...

Cite
Perumpail RB, Hahambis TA, Aggarwal A, et al. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol. 2016;8(1):69-73doi: 10.4254/wjh.v8.i1.69.
Perumpail, R. B., Hahambis, T. A., Aggarwal, A., Younossi, Z. M., & Ahmed, A. (2016). Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World journal of hepatology, 8(1), 69-73. https://doi.org/10.4254/wjh.v8.i1.69
Perumpail, Ryan B, et al. "Treatment strategies for chronic hepatitis C prior to and following liver transplantation." World journal of hepatology vol. 8,1 (2016): 69-73. doi: https://doi.org/10.4254/wjh.v8.i1.69
Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol. 2016 Jan 08;8(1):69-73. doi: 10.4254/wjh.v8.i1.69. PMID: 26783422; PMCID: PMC4705454.
Copy Download .nbib Format: NLM
Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease.

BMJ open gastroenterology

Sayiner M, Stepanova M, Pham H, Noor B, Walters M, Younossi ZM.
PMID: 27648297
BMJ Open Gastroenterol. 2016 Aug 16;3(1):e000106. doi: 10.1136/bmjgast-2016-000106. eCollection 2016.

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease associated with increased liver-related mortality. Additionally, NAFLD could potentially impair health-related quality of life. Although an approved treatment for NAFLD does not...

Cite
Sayiner M, Stepanova M, Pham H, et al. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016;3(1):e000106doi: 10.1136/bmjgast-2016-000106.
Sayiner, M., Stepanova, M., Pham, H., Noor, B., Walters, M., & Younossi, Z. M. (2016). Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ open gastroenterology, 3(1), e000106. https://doi.org/10.1136/bmjgast-2016-000106
Sayiner, Mehmet, et al. "Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease." BMJ open gastroenterology vol. 3,1 (2016): e000106. doi: https://doi.org/10.1136/bmjgast-2016-000106
Sayiner M, Stepanova M, Pham H, Noor B, Walters M, Younossi ZM. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016 Aug 16;3(1):e000106. doi: 10.1136/bmjgast-2016-000106. eCollection 2016. PMID: 27648297; PMCID: PMC5013331.
Copy Download .nbib Format: NLM
Screening of Fetal Chromosome Aneuploidies in the First and Second Trimester of 125,170 Iranian Pregnant Women.

Iranian journal of public health

Seyyed Kavoosi E, Younessi S, Farhud DD.
PMID: 26258091
Iran J Public Health. 2015 Jun;44(6):791-6.

BACKGROUND: Aneuploidy is one of the main causes of congenital anomalies, mental and physical disabilities, in newborns. The aim of this study was to determine various chromosomal aneuploidies in the first and second trimester screening of pregnant women, in...

Cite
Seyyed Kavoosi E, Younessi S, Farhud DD. Screening of Fetal Chromosome Aneuploidies in the First and Second Trimester of 125,170 Iranian Pregnant Women. Iran J Public Health. 2015;44(6):791-6
Seyyed Kavoosi, E., Younessi, S., & Farhud, D. D. (2015). Screening of Fetal Chromosome Aneuploidies in the First and Second Trimester of 125,170 Iranian Pregnant Women. Iranian journal of public health, 44(6), 791-6.
Seyyed Kavoosi, Elham, et al. "Screening of Fetal Chromosome Aneuploidies in the First and Second Trimester of 125,170 Iranian Pregnant Women." Iranian journal of public health vol. 44,6 (2015): 791-6.
Seyyed Kavoosi E, Younessi S, Farhud DD. Screening of Fetal Chromosome Aneuploidies in the First and Second Trimester of 125,170 Iranian Pregnant Women. Iran J Public Health. 2015 Jun;44(6):791-6. PMID: 26258091; PMCID: PMC4524303.
Copy Download .nbib Format: NLM
Quo vadis: from oxidative stress to gamma-glutamyltransferase upregulation to mortality.

Journal of clinical and experimental hepatology

Mehta R, Birerdinc A, Younossi Z.
PMID: 25755465
J Clin Exp Hepatol. 2013 Mar;3(1):2-3. doi: 10.1016/j.jceh.2013.02.004.

No abstract available.

Cite
Mehta R, Birerdinc A, Younossi Z. Quo vadis: from oxidative stress to gamma-glutamyltransferase upregulation to mortality. J Clin Exp Hepatol. 2013;3(1):2-3doi: 10.1016/j.jceh.2013.02.004.
Mehta, R., Birerdinc, A., & Younossi, Z. (2013). Quo vadis: from oxidative stress to gamma-glutamyltransferase upregulation to mortality. Journal of clinical and experimental hepatology, 3(1), 2-3. https://doi.org/10.1016/j.jceh.2013.02.004
Mehta, Rohini, et al. "Quo vadis: from oxidative stress to gamma-glutamyltransferase upregulation to mortality." Journal of clinical and experimental hepatology vol. 3,1 (2013): 2-3. doi: https://doi.org/10.1016/j.jceh.2013.02.004
Mehta R, Birerdinc A, Younossi Z. Quo vadis: from oxidative stress to gamma-glutamyltransferase upregulation to mortality. J Clin Exp Hepatol. 2013 Mar;3(1):2-3. doi: 10.1016/j.jceh.2013.02.004. PMID: 25755465; PMCID: PMC3940520.
Copy Download .nbib Format: NLM
Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.

Annals of hepatology

Birerdinc A, Younossi ZM.
PMID: 29311407
Ann Hepatol. 2018 January-February;17(1):11-13. doi: 10.5604/01.3001.0010.7530.

No abstract available.

Cite
Birerdinc A, Younossi ZM. Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Ann Hepatol. 2018;17(1):11-13doi: 10.5604/01.3001.0010.7530.
Birerdinc, A., & Younossi, Z. M. (2018). Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Annals of hepatology, 17(1), 11-13. https://doi.org/10.5604/01.3001.0010.7530
Birerdinc, Aybike, and Younossi, Zobair M. "Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis." Annals of hepatology vol. 17,1 (2018): 11-13. doi: https://doi.org/10.5604/01.3001.0010.7530
Birerdinc A, Younossi ZM. Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Ann Hepatol. 2018 January-February;17(1):11-13. doi: 10.5604/01.3001.0010.7530. PMID: 29311407.
Copy Download .nbib Format: NLM
Reply.

Hepatology (Baltimore, Md.)

Ahmed A, Beckerman R, Younossi ZM.
PMID: 28960407
Hepatology. 2018 Jan;67(1):450-451. doi: 10.1002/hep.29555.

No abstract available.

Cite
Ahmed A, Beckerman R, Younossi ZM. Reply. Hepatology. 2018;67(1):450-451doi: 10.1002/hep.29555.
Ahmed, A., Beckerman, R., & Younossi, Z. M. (2018). Reply. Hepatology (Baltimore, Md.), 67(1), 450-451. https://doi.org/10.1002/hep.29555
Ahmed, Aijaz, et al. "Reply." Hepatology (Baltimore, Md.) vol. 67,1 (2018): 450-451. doi: https://doi.org/10.1002/hep.29555
Ahmed A, Beckerman R, Younossi ZM. Reply. Hepatology. 2018 Jan;67(1):450-451. doi: 10.1002/hep.29555. PMID: 28960407.
Copy Download .nbib Format: NLM
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease.

Hepatology communications

Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhlouf H, Goodman Z.
PMID: 29404470
Hepatol Commun. 2017 Jun 06;1(5):421-428. doi: 10.1002/hep4.1054. eCollection 2017 Jul.

Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD). The minimal pathologic criteria for NASH include hepatic steatosis, ballooning degeneration, and lobular inflammation. The resolution of NASH, which relies on the loss of ballooning degeneration,...

Cite
Younossi ZM, Stepanova M, Rafiq N, et al. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatol Commun. 2017;1(5):421-428doi: 10.1002/hep4.1054.
Younossi, Z. M., Stepanova, M., Rafiq, N., Henry, L., Loomba, R., Makhlouf, H., & Goodman, Z. (2017). Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatology communications, 1(5), 421-428. https://doi.org/10.1002/hep4.1054
Younossi, Zobair M, et al. "Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease." Hepatology communications vol. 1,5 (2017): 421-428. doi: https://doi.org/10.1002/hep4.1054
Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhlouf H, Goodman Z. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatol Commun. 2017 Jun 06;1(5):421-428. doi: 10.1002/hep4.1054. eCollection 2017 Jul. PMID: 29404470; PMCID: PMC5721410.
Copy Download .nbib Format: NLM
Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality.

Hepatology communications

Shahab O, Biswas R, Paik J, Bush H, Golabi P, Younossi ZM.
PMID: 30288477
Hepatol Commun. 2018 Sep 24;2(10):1227-1234. doi: 10.1002/hep4.1241. eCollection 2018 Oct.

Dyslipidemia is one of the common risk factors for NAFLD and is associated with cardiovascular (CV) mortality, which is the most common cause of death in NAFLD. Lipid-lowering agents (LLAs) are used to reduce CV events in the general...

Cite
Shahab O, Biswas R, Paik J, et al. Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. Hepatol Commun. 2018;2(10):1227-1234doi: 10.1002/hep4.1241.
Shahab, O., Biswas, R., Paik, J., Bush, H., Golabi, P., & Younossi, Z. M. (2018). Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. Hepatology communications, 2(10), 1227-1234. https://doi.org/10.1002/hep4.1241
Shahab, Omer, et al. "Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality." Hepatology communications vol. 2,10 (2018): 1227-1234. doi: https://doi.org/10.1002/hep4.1241
Shahab O, Biswas R, Paik J, Bush H, Golabi P, Younossi ZM. Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. Hepatol Commun. 2018 Sep 24;2(10):1227-1234. doi: 10.1002/hep4.1241. eCollection 2018 Oct. PMID: 30288477; PMCID: PMC6167074.
Copy Download .nbib Format: NLM
Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease.

BMJ open gastroenterology

Mehta R, Otgonsuren M, Younoszai Z, Allawi H, Raybuck B, Younossi Z.
PMID: 27493762
BMJ Open Gastroenterol. 2016 Jul 26;3(1):e000096. doi: 10.1136/bmjgast-2016-000096. eCollection 2016.

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and coronary artery disease (CAD) is the cardiac manifestation of metabolic syndrome. NAFLD is strongly linked to CAD and hepatic steatosis is an independent risk factor...

Cite
Mehta R, Otgonsuren M, Younoszai Z, et al. Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ Open Gastroenterol. 2016;3(1):e000096doi: 10.1136/bmjgast-2016-000096.
Mehta, R., Otgonsuren, M., Younoszai, Z., Allawi, H., Raybuck, B., & Younossi, Z. (2016). Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ open gastroenterology, 3(1), e000096. https://doi.org/10.1136/bmjgast-2016-000096
Mehta, Rohini, et al. "Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease." BMJ open gastroenterology vol. 3,1 (2016): e000096. doi: https://doi.org/10.1136/bmjgast-2016-000096
Mehta R, Otgonsuren M, Younoszai Z, Allawi H, Raybuck B, Younossi Z. Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ Open Gastroenterol. 2016 Jul 26;3(1):e000096. doi: 10.1136/bmjgast-2016-000096. eCollection 2016. PMID: 27493762; PMCID: PMC4964159.
Copy Download .nbib Format: NLM
Hepatitis C and metabolic syndrome.

Expert review of endocrinology & metabolism

Estep JM, Younossi ZM.
PMID: 30764047
Expert Rev Endocrinol Metab. 2010 Mar;5(2):209-215. doi: 10.1586/eem.10.7.

Hepatitis C virus (HCV) and the hepatic manifestation of metabolic syndrome, nonalcoholic fatty liver disease, are the two major causes of chronic liver disease worldwide. Liver histology of both diseases can be associated with steatosis, oxidative stress and fibrogenesis....

Cite
Estep JM, Younossi ZM. Hepatitis C and metabolic syndrome. Expert Rev Endocrinol Metab. 2010;5(2):209-215doi: 10.1586/eem.10.7.
Estep, J. M., & Younossi, Z. M. (2010). Hepatitis C and metabolic syndrome. Expert review of endocrinology & metabolism, 5(2), 209-215. https://doi.org/10.1586/eem.10.7
Estep, J Michael, and Younossi, Zobair M. "Hepatitis C and metabolic syndrome." Expert review of endocrinology & metabolism vol. 5,2 (2010): 209-215. doi: https://doi.org/10.1586/eem.10.7
Estep JM, Younossi ZM. Hepatitis C and metabolic syndrome. Expert Rev Endocrinol Metab. 2010 Mar;5(2):209-215. doi: 10.1586/eem.10.7. PMID: 30764047.
Copy Download .nbib Format: NLM
Overall health-related quality of life in patients with end-stage liver disease.

Clinical liver disease

Younossi Z, Henry L.
PMID: 31040976
Clin Liver Dis (Hoboken). 2015 Jul 28;6(1):9-14. doi: 10.1002/cld.480. eCollection 2015 Jul.

No abstract available.

Cite
Younossi Z, Henry L. Overall health-related quality of life in patients with end-stage liver disease. Clin Liver Dis (Hoboken). 2015;6(1):9-14doi: 10.1002/cld.480.
Younossi, Z., & Henry, L. (2015). Overall health-related quality of life in patients with end-stage liver disease. Clinical liver disease, 6(1), 9-14. https://doi.org/10.1002/cld.480
Younossi, Zobair, and Henry, Linda. "Overall health-related quality of life in patients with end-stage liver disease." Clinical liver disease vol. 6,1 (2015): 9-14. doi: https://doi.org/10.1002/cld.480
Younossi Z, Henry L. Overall health-related quality of life in patients with end-stage liver disease. Clin Liver Dis (Hoboken). 2015 Jul 28;6(1):9-14. doi: 10.1002/cld.480. eCollection 2015 Jul. PMID: 31040976; PMCID: PMC6490633.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 123 entries